PMID

Data

Article Title

Organization

Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists.

University of Camerino

Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.

University of Bonn

Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.

Roche Palo Alto

Discovery of P2X3 selective antagonists for the treatment of chronic pain.

Astrazeneca

Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.

University of Bonn

Purine and pyrimidine (P2) receptors as drug targets.

National Institute of Diabetes

Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

Roche Palo Alto

Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

Roche Palo Alto

Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists.

Shionogi

Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.

National Institute of Diabetes and Digestive and Kidney Diseases

Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion.

Gwangju Institute of Science and Technology (Gist)

A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.

National Institute of Diabetes and Digestive and Kidney Diseases

Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells.

Gwangju Institute of Science and Technology (Gist)

Nicotinyl aspartyl ketones as inhibitors of caspase-3.

Merck Frosst Canada

Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.

Saarland University